Stemedicus AB

ABActive

Org 5566127071Odengatan 29, 113 51 StockholmResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2001 · 25 years old0 employees

Overview

Stemedicus AB is a Swedish AB based in Stockholm, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2001, the company has 0 employees and reported revenue of SEK 6.3k in its latest annual filing.

Revenue 2024

6.3K SEK

+3009% vs 2023

EBITDA margin

39.6 %

+160% vs 2023

Net profit 2024

9.8K SEK

+404% vs 2023

Key ratios

See full ratios →

>999 %

20202024

0.0×

Very weak

Among the 10% lowest rated companies in the industry

20202024

>999 %

20202024

EBITDA — year on year

SEK thousands

Key figures

Annual report 2024

Revenue	6.3K SEK	+3009%
EBITDA	2.5K SEK	+160%
Net profit	9.8K SEK	+404%
Total assets	0K SEK	-100%
Equity	329.5K SEK	+3%
Employees	0	—

Financial development

In its most recent annual report (2024), Stemedicus AB reported revenue of SEK 6.3k, an increase of 3009% on the year before. The figures on this page draw on 5 annual filings covering 2020 to 2024. The bottom line showed a net profit of SEK 9.8k, and the EBITDA margin stood at 39.6%.

At the end of 2024, current assets covered short-term debt 0 times.

Financials

Revenue

SEK

EBITDA

SEK thousands

Income statement

SEK thousands

Item	2024	2023	2022	2021	2020
Revenue	6	0	0	0	4
Staff expenses	-0	-0	-0	—	—
EBITDA	2	-4	-20	-6	-5
Depreciation & amort.	-0	-0	-0	-3	-0
EBIT	2	-4	-20	-9	-5
Net financials	7	6	1	1	1
Profit before tax	10	2	-19	-8	-4
Tax	-0	-0	-0	-0	-0
Net profit	10	2	-19	-8	-4

Get a credit rating – not just the numbers

Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.

See the credit rating

Balance sheet

SEK thousands

Item	2024	2023	2021	2020
Total assets	0	379	391	388
Equity	329	320	336	344
Long-term debt	57	57	52	39
Short-term debt	2	2	3	4
Total debt	59	59	55	43

Financial ratios

5-year trend

EBITDA margin

39.6 %

20202024

Equity ratio

>999 %

20202024

Return on equity

3.0 %

Average

Around the average of companies in the same industry

20202024

Net profit margin

156.8 %

Very strong

Among the 10% highest rated companies in the industry

20202024

Asset turnover

>999×

20202024

Debt / equity

-1.00×

Strong

Among the 40% highest rated companies in the industry

20202024

Sector performance

19 of 28 ratios graded

28 financial ratios from the latest filing, each graded against companies in the same industry.

Profitability

Gross marginVery weak

Among the 10% lowest rated companies in the industry

The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.

Operating marginStrong

Among the 30% highest rated companies in the industry

EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.

Net profit marginVery strong

Among the 10% highest rated companies in the industry

The profit for the year as a share of revenue — the company's ability to turn revenue into profit.

Return on equity (ROE)Average

Around the average of companies in the same industry

Net profit as a percentage of equity — the return the owners earned on their invested capital this year.

Return on assets (ROA)Not rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Net profit as a percentage of total assets — the return generated on the capital employed.

Return on net assets (RONA)Not rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.

Basic earning power (BEP)Not rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.

Capacity ratioNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.

Liquidity

Current ratioVery weak

Among the 10% lowest rated companies in the industry

Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.

Quick ratioVery weak

Among the 10% lowest rated companies in the industry

Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.

Cash ratioVery weak

Among the 10% lowest rated companies in the industry

Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.

Current assets to equityVery strong

Among the 10% highest rated companies in the industry

Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.

Fixed assets to long-term capitalVery strong

Among the 10% highest rated companies in the industry

Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.

Cash conversion ratioWeak

Among the 30% lowest rated companies in the industry

Cash flow relative to profit — the ability to convert reported profits into accessible cash.

Debt & solvency

Debt to equityStrong

Among the 40% highest rated companies in the industry

Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.

Liabilities to equityStrong

Among the 30% highest rated companies in the industry

Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.

Income to debtAverage

Around the average of companies in the same industry

Profit relative to debt — the ability to create earnings while operating with debt.

EBITDA to debtAverage

Around the average of companies in the same industry

EBITDA relative to debt — how much operating earnings are available to service the debt.

Interest rate on debtVery strong

Among the 10% highest rated companies in the industry

Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.

Interest marginAverage

Around the average of companies in the same industry

The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.

Solidity ratioNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.

Debt ratioNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.

Interest coverageNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The ability to pay the interest on the company's debt out of its earnings.

Efficiency & development

Equity to contributed capitalWeak

Among the 40% lowest rated companies in the industry

Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.

One-year change in equityAverage

Around the average of companies in the same industry

The size of this year's increase or decrease in the company's equity.

One-year change in debtAverage

Around the average of companies in the same industry

The size of this year's increase or decrease in the company's debt.

Asset turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to total assets — the ability to generate revenue from the asset base.

Inventory turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.

Annual reports & filings

Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31

People & ownership

Management

Actively employed in the business

Name	Role	Member since

Former (1)


AG Anders Gabriel Lundgren Audit	Audit	2020 – 2022

Board of directors

Non-executive oversight

Name	Role	Member since
Current (2)
LÅ Leif Åke Lassas Stenke Board of Directors	Board of Directors	2020
RH Rolf Hans Lassas Stenke Deputy Board Member	Deputy Board Member	2020

Shareholders

Active legal owners

No shareholder data available.

One in three Danish companies experiences fraud

Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.

See the fraud module

Related companies

Company hierarchy

No registered parent or subsidiaries

Board network connections

Board members of Stemedicus AB also hold positions in 119 other companies.

Person	Role here	Other companies
Anders Gabriel Lundgren	Audit	118 companiesMany roles
Leif Åke Lassas Stenke	Board of Directors	1 company

Frequently asked questions

What is the Org number of Stemedicus AB?

Stemedicus AB is registered with Bolagsverket / SCB under Org 5566127071.

What is the revenue of Stemedicus AB?

Stemedicus AB reported revenue of SEK 6.3k in 2024.

Where is Stemedicus AB headquartered?

Stemedicus AB's registered address is Odengatan 29.